29 June 2012, Melbourne: The Board of HealthLinx Limited (ASX:HTX) is pleased to announce the appointment of a General Manager for Australian Operations, Ms Vanessa Waddell effective 1 July 2012. Ms Waddell formally joins the company after consulting to the company in 2011 on business development and regulatory strategy. Ms Waddell brings to the role more than 15 years of industry experience including 7 years at executive management level. Her expertise is in the immunology sector, specifically oncology and more specifically in the development of ovarian cancer therapeutics, thus bringing to HealthLinx knowledge and experience that is targeted to the development and marketing of the company’s lead product, OvPlex™
HTX Price at posting:
0.4¢ Sentiment: Hold Disclosure: Held